Aberrant expression of PTK2, MAPK signaling pathway, PI3K-Akt signaling pathway, p53 signaling pathway and MET were closely associated with EC carcinogenesis.
C-Met overexpression was significantly associated with shorter OS (HR: 2.04, 95% CI: 1.66-2.52, P<0.001) and DSS (HR: 3.03, 95% CI: 2.04-4.48, P<0.001) in patients with EC.
Amplified genes were noted in 37% of gastric/esophageal tumors, including in therapeutically targetable kinases such as ERBB2, FGFR1, FGFR2, EGFR, and MET, suggesting the potential use of genomic amplifications as biomarkers to guide therapy of gastric and esophageal cancers where targeted therapeutics have been less developed compared with colorectal cancers.